Answers are grounded in this paper and cite their sources.
Pharmacological activation of GPR55 mitigates cognitive deficits in neuropathic pain, suggesting its potential therapeutic role in neuroinflammation and microglial polarization.
Cognitive impairment induced by neuropathic pain substantially diminishes quality of life, with hippocampal neuroinflammation identified as a critical pathogenic factor. Although G protein-coupled receptor 55 (GPR55) demonstrates anti-inflammatory, analgesic, and neuroprotective properties, its therapeutic potential and molecular mechanisms in neuropathic pain-induced cognitive deficits remain uncharacterized. Using a spared nerve injury (SNI) mouse model, we systematically investigated GPR55's neuroprotective mechanisms. Pharmacological activation of GPR55 effectively ameliorated cognitive dysfunction and attenuated hippocampal neuroinflammation and preserved synaptic plasticity by shifting microglial polarization toward the neuroprotective M2 phenotype in SNI mice. Mechanistic studies revealed that the immunomodulatory effects operate through the CaMKKβ/AMPK/SOCS3 signaling axis, as confirmed by pathway blockade using the specific inhibitor Compound C. These results demonstrate that GPR55 activation modulates microglial polarization, mitigates neuroinflammatory cascades, and preserves synaptic plasticity, thus alleviating neuropathic pain-associated cognitive dysfunction through a mechanism involving the CaMKKβ/AMPK/SOCS3 signaling pathway.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: